مؤتمر
أعرض في EDS

#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

التفاصيل البيبلوغرافية
العنوان: #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
المؤلفون: Banerjee, Susana N, Ring, Kari L, Niewenhuysen, Els Van, Fabbro, Michel, Aghajanian, Carol, Oaknin, Ana, Colombo, Nicoletta, Santin, Alessandro D, Clamp, Andrew R, Moore, Kathleen N, Rose, Peter G, David M, O’Malley, Chon, Hye Sook, Salinas, Erin A, Prendergast, Emily N, Lustgarten, Stephanie, Rodrigues, Manuel, Gennigens, Christine, Monk, Bradley J, Grisham, Rachel N
المصدر: International Journal of Gynecological Cancer, 33, A20-A21 (2023-09); ESGO's 24th European Gynaecological Oncology Congress, 28/09/2023 au 1/10/2023
سنة النشر: 2023
مصطلحات موضوعية: Human health sciences, Oncology, Reproductive medicine (gynecology, andrology, obstetrics), Sciences de la santé humaine, Oncologie, Médecine de la reproduction (Gynécologie, andrologie, obstétrique)
نوع الوثيقة: conference paper
http://purl.org/coar/resource_type/c_5794Test
conferenceObject
peer reviewed
اللغة: English
العلاقة: https://syndication.highwire.org/content/doi/10.1136/ijgc-2023-ESGO.29Test; urn:issn:1525-1438
DOI: 10.1136/ijgc-2023-esgo.29
الوصول الحر: https://orbi.uliege.be/handle/2268/310283Test
حقوق: restricted access
http://purl.org/coar/access_right/c_16ecTest
info:eu-repo/semantics/restrictedAccess
رقم الانضمام: edsorb.310283
قاعدة البيانات: ORBi
الوصف
DOI:10.1136/ijgc-2023-esgo.29